Monday, December 24, 2012
Most of the genomics pioneers fell short in their attempts to
turn vast amounts of sequence data into drugs, as the task turned out to be far
more complex than anyone imagined at the time. Now, more than a decade later, Amgen
Inc. thinks it can succeed where one of those pioneers, deCode
Genetics ehf, failed.
This month, Amgen proposed to
acquire deCode for $415 million in cash. The deal includes genomic and clinical
data from more than 140,000 Icelandic individuals along with deCode's
proprietary algorithms and genealogy information on the entire population. The
deal is expected to close by year end.